For research use only
| Cat No. | ABC-TC1333 |
| Product Type | Human Esophageal Cancer Cell Lines |
| Cell Type | Epithelial-like |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Disease | Esophageal Squamous Cell Cancer |
| Product Code | KYSE 410; KYSE410; Kyse410; KYSE0410 |
KYSE410 esophageal squamous carcinoma cells enable invasion, signaling, and chemotherapeutic response studies in poorly differentiated ESCC models.
KYSE410 is a human esophageal squamous cell carcinoma (ESCC) cell line derived from a poorly differentiated, invasive tumor resected from a 51-year-old Japanese male patient. The cells grow as adherent monolayers with epithelial morphology and display a population doubling time of approximately 32–45 hours. KYSE 410 harbors key oncogenic alterations, including TP53 and KRAS mutations, and shows hypermethylation of the p16 (INK4a) promoter, leading to cell cycle deregulation. They demonstrates overexpresses of oncogenic markers such as heparin-binding growth factor (hst-1) and cyclin D1. Cytogenetic studies reveal complex aneuploidy with gains at chromosome arms such as 2q, 3, 8, 17p, and X, and isochromosome 3q formations consistent with ESCC genomic instability. The cell line is tumorigenic in nude mice, readily forming subcutaneous tumors upon xenotransplantation. KYSE 410 thus offers a robust model for ESCC pathogenesis, tumor epigenetics, and in vivo therapeutic evaluation.
| Product Code | KYSE 410; KYSE410; Kyse410; KYSE0410 |
| Species | Human |
| Cat.No | ABC-TC1333 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial-like |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Disease | Esophageal Squamous Cell Cancer |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Esophageal Cancer Cell Lines |
The KYSE410 cell line serves as a valuable in vitro model for studying pathogenesis and molecular biology of human esophageal squamous cell carcinoma. Its tumorigenic properties and defined mutational landscape make it particularly suited for investigating oncogenic signaling pathways, especially those involving TP53 and KRAS mutations. Researchers commonly utilize KYSE410 in preclinical drug screening, evaluating the efficacy of chemotherapeutic agents and targeted therapies, including inhibitors of EGFR and cyclin D1 pathways. Additionally, the cell line supports studies on tumor progression, metastasis, and resistance mechanisms, contributing to the development of novel therapeutic strategies for ESCC.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
